Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, with a satisfactory Voluntary Action Indicated (VAI) classification. The inspection was conducted from April 13, 2026, to April 17, 2026.
Nilesh Gupta, Managing Director, Lupin, said, “We are pleased to receive the EIR with a VAI classification from the U.S. FDA for our Somerset facility. This outcome reflects our unwavering commitment to quality, compliance, and operational excellence and reinforces our dedication to manufacturing high-quality medicines that patients around the world can trust.”
